A phase II study of combination daunorubicin, cytarabine (Ara-c), and nilotinib (TAsigna) (DATA) in patients newly diagnosed with acute myeloid leukemia with KIT expression

Aref Al-Kali, Raoul Tibes, Pamela Atherton, Jeanne Palmer, Hassan B. Alkhateeb, Mrinal Patnaik, Kebede Begna, Naseema Gangat, Shahrukh Hashmi, Rong He, Mark Litzow

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'A phase II study of combination daunorubicin, cytarabine (Ara-c), and nilotinib (TAsigna) (DATA) in patients newly diagnosed with acute myeloid leukemia with KIT expression'. Together they form a unique fingerprint.

Medicine & Life Sciences